Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
24.06
-0.57 (-2.29%)
Jun 25, 2025, 10:10 AM - Market open
Pacira BioSciences Revenue
Pacira BioSciences had revenue of $168.92M in the quarter ending March 31, 2025, with 1.08% growth. This brings the company's revenue in the last twelve months to $702.77M, up 3.08% year-over-year. In the year 2024, Pacira BioSciences had annual revenue of $700.97M with 3.85% growth.
Revenue (ttm)
$702.77M
Revenue Growth
+3.08%
P/S Ratio
1.62
Revenue / Employee
$889,585
Employees
790
Market Cap
1.11B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 700.97M | 25.99M | 3.85% |
Dec 31, 2023 | 674.98M | 8.16M | 1.22% |
Dec 31, 2022 | 666.82M | 125.29M | 23.14% |
Dec 31, 2021 | 541.53M | 111.89M | 26.04% |
Dec 31, 2020 | 429.65M | 8.62M | 2.05% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PCRX News
- 8 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Shareholders to Inquire about Securities Investigation - Accesswire
- 10 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Connect - Accesswire
- 13 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Stockholders to Inquire about Securities Investigation - Accesswire
- 15 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation - Accesswire
- 17 days ago - Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 20 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect - Accesswire
- 20 days ago - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 24 days ago - Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Accesswire